MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and Generate:Biomedicines formed a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login